{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T16:32:57Z","timestamp":1787243577439,"version":"build-2736575974"},"reference-count":288,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2025,1,16]],"date-time":"2025-01-16T00:00:00Z","timestamp":1736985600000},"content-version":"unspecified","delay-in-days":15,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2024,12,12]]},"published-print":{"date-parts":[[2025,1]]},"abstract":"<jats:p>Cancer immunotherapy\u2014including immune checkpoint inhibition (ICI) and adoptive cell therapy (ACT)\u2014has become a standard, potentially curative treatment for a subset of advanced solid and liquid tumors. However, most patients with cancer do not benefit from the rapidly evolving improvements in the understanding of principal mechanisms determining cancer immune responsiveness (CIR); including patient-specific genetically determined and acquired factors, as well as intrinsic cancer cell biology. Though CIR is multifactorial, fundamental concepts are emerging that should be considered for the design of novel therapeutic strategies and related clinical studies. Recent advancements as well as novel approaches to address the limitations of current treatments are discussed here, with a specific focus on ICI and ACT.<\/jats:p>","DOI":"10.1136\/jitc-2024-008876","type":"journal-article","created":{"date-parts":[[2025,1,17]],"date-time":"2025-01-17T03:00:32Z","timestamp":1737082832000},"page":"e008876","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":18,"title":["Advances in the understanding and therapeutic manipulation of cancer immune responsiveness: a Society for Immunotherapy of Cancer (SITC) review"],"prefix":"10.1136","volume":"13","clinical-trial-number":[{"clinical-trial-number":"nct04185883","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04074967","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04294810","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04401995","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00586391","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03089203","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04623944","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Alessandra","family":"Cesano","sequence":"first","affiliation":[{"name":"ESSA Pharma Inc, South San Francisco, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan","family":"Augustin","sequence":"additional","affiliation":[{"name":"University of Pittsburgh Department of Medicine, Pittsburgh, Pennsylvania, USA"},{"name":"Mayo Clinic, Rochester, Minnesota, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigi","family":"Barrea","sequence":"additional","affiliation":[{"name":"Universit\u00e0 Telematica Pegaso, Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davide","family":"Bedognetti","sequence":"additional","affiliation":[{"name":"Kite Pharma Inc, Santa Monica, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tullia C","family":"Bruno","sequence":"additional","affiliation":[{"name":"University of Pittsburgh, UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2711-5724","authenticated-orcid":false,"given":"Alberto","family":"Carturan","sequence":"additional","affiliation":[{"name":"University of Pennsylvania, Philadelphia, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Hammer","sequence":"additional","affiliation":[{"name":"Altos Labs Inc, San Fransisco, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Winson S","family":"Ho","sequence":"additional","affiliation":[{"name":"University of California San Francisco, San Francisco, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jakob Nikolas","family":"Kather","sequence":"additional","affiliation":[{"name":"Else Kroener Fresenius Center for Digital Health, Technical University Dresden, Dresden, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomas","family":"Kirchhoff","sequence":"additional","affiliation":[{"name":"Laura and Isaac Perlmutter Cancer Center, New York University Grossman School of Medicine, New York University Langone Health, New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rongze O","family":"Lu","sequence":"additional","affiliation":[{"name":"UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"McQuade","sequence":"additional","affiliation":[{"name":"University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0138-1664","authenticated-orcid":false,"given":"Yana G","family":"Najjar","sequence":"additional","affiliation":[{"name":"UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Violena","family":"Pietrobon","sequence":"additional","affiliation":[{"name":"Kite Pharma Inc, Santa Monica, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4301-5811","authenticated-orcid":false,"given":"Marco","family":"Ruella","sequence":"additional","affiliation":[{"name":"University of Pennsylvania, Philadelphia, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rhine","family":"Shen","sequence":"additional","affiliation":[{"name":"Kite Pharma Inc, Santa Monica, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Soldati","sequence":"additional","affiliation":[{"name":"University of Milan, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Spencer","sequence":"additional","affiliation":[{"name":"Parker Institute for Cancer Immunotherapy, San Francisco, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6422-2997","authenticated-orcid":false,"given":"Allison","family":"Betof Warner","sequence":"additional","affiliation":[{"name":"Stanford University School of Medicine, Stanford, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5046-2890","authenticated-orcid":false,"given":"Sarah","family":"Warren","sequence":"additional","affiliation":[{"name":"Kite Pharma Inc, Santa Monica, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elad","family":"Ziv","sequence":"additional","affiliation":[{"name":"University of California San Francisco, San Francisco, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco M","family":"Marincola","sequence":"additional","affiliation":[{"name":"Sonata Therapeutics Inc, Watertown, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,1,16]]},"reference":[{"key":"2025100300562845000_13.1.e008876.1","doi-asserted-by":"publisher","DOI":"10.1038\/nrg.2015.33"},{"key":"2025100300562845000_13.1.e008876.2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2013.08.041"},{"key":"2025100300562845000_13.1.e008876.3","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1038\/s41586-022-04447-0","article-title":"Human genetic and immunological determinants of critical COVID-19 pneumonia","volume":"603","author":"Zhang","year":"2022","journal-title":"Nature New Biol"},{"key":"2025100300562845000_13.1.e008876.4","doi-asserted-by":"publisher","DOI":"10.1159\/000369902"},{"key":"2025100300562845000_13.1.e008876.5","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/978-1-4939-9773-2_4","article-title":"Germline Genetics in Immuno-oncology: From Genome-Wide to Targeted Biomarker Strategies","volume":"2055","author":"Kirchhoff","year":"2020","journal-title":"Methods Mol Biol"},{"key":"2025100300562845000_13.1.e008876.6","doi-asserted-by":"crossref","DOI":"10.1186\/1479-5876-10-170","article-title":"IRF5 gene polymorphisms in melanoma","volume":"10","author":"Uccellini","year":"2012","journal-title":"J Transl Med"},{"key":"2025100300562845000_13.1.e008876.7","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2013.557"},{"key":"2025100300562845000_13.1.e008876.8","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-007-0407-z"},{"key":"2025100300562845000_13.1.e008876.9","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2017.00386","article-title":"Association of CTLA-4 Gene Variants with Response to Therapy and Long-term Survival in Metastatic Melanoma Patients Treated with Ipilimumab: An Italian Melanoma Intergroup Study","volume":"8","author":"Queirolo","year":"2017","journal-title":"Front Immunol"},{"key":"2025100300562845000_13.1.e008876.10","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2018.02.010"},{"key":"2025100300562845000_13.1.e008876.11","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-019-02318-8"},{"key":"2025100300562845000_13.1.e008876.12","doi-asserted-by":"publisher","DOI":"10.1126\/science.aao4572"},{"key":"2025100300562845000_13.1.e008876.13","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2021.12.006"},{"key":"2025100300562845000_13.1.e008876.14","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00582-9"},{"key":"2025100300562845000_13.1.e008876.15","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2019.9292","article-title":"Association of Germline Variants in Natural Killer Cells With Tumor Immune Microenvironment Subtypes, Tumor-Infiltrating Lymphocytes, Immunotherapy Response, Clinical Outcomes, and Cancer Risk","volume":"2","author":"Xu","year":"2019","journal-title":"JAMA Netw Open"},{"key":"2025100300562845000_13.1.e008876.16","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2021.01.011"},{"key":"2025100300562845000_13.1.e008876.17","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2018.03.023"},{"key":"2025100300562845000_13.1.e008876.18","doi-asserted-by":"crossref","DOI":"10.1016\/j.xpro.2022.101809","article-title":"Analytic pipelines to assess the relationship between immune response and germline genetics in human tumors","volume":"3","author":"Sayaman","year":"2022","journal-title":"STAR Protoc"},{"key":"2025100300562845000_13.1.e008876.19","doi-asserted-by":"crossref","first-page":"2900","DOI":"10.1016\/j.celrep.2020.02.039","article-title":"Germline Features Associated with Immune Infiltration in Solid Tumors","volume":"30","author":"Shahamatdar","year":"2020","journal-title":"Cell Rep"},{"key":"2025100300562845000_13.1.e008876.20","doi-asserted-by":"publisher","DOI":"10.1038\/ng.2933"},{"key":"2025100300562845000_13.1.e008876.21","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.567348","article-title":"Polymorphisms in STING Affect Human Innate Immune Responses to Poxviruses","volume":"11","author":"Kennedy","year":"2020","journal-title":"Front Immunol"},{"key":"2025100300562845000_13.1.e008876.22","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-023-38271-5","article-title":"Germline modifiers of the tumor immune microenvironment implicate drivers of cancer risk and immunotherapy response","volume":"14","author":"Pagadala","year":"2023","journal-title":"Nat Commun"},{"key":"2025100300562845000_13.1.e008876.23","doi-asserted-by":"crossref","DOI":"10.1126\/science.adh8697","article-title":"Germline-mediated immunoediting sculpts breast cancer subtypes and metastatic proclivity","volume":"384","author":"Houlahan","year":"2024","journal-title":"Science"},{"key":"2025100300562845000_13.1.e008876.24","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1703481"},{"key":"2025100300562845000_13.1.e008876.25","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1003466"},{"key":"2025100300562845000_13.1.e008876.26","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1501824"},{"key":"2025100300562845000_13.1.e008876.27","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-med-050219-034237"},{"key":"2025100300562845000_13.1.e008876.28","doi-asserted-by":"publisher","DOI":"10.1038\/S41591-022-02094-6"},{"key":"2025100300562845000_13.1.e008876.29","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdw640"},{"key":"2025100300562845000_13.1.e008876.30","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-0921"},{"key":"2025100300562845000_13.1.e008876.31","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-021-23661-4","article-title":"Genetic variation associated with thyroid autoimmunity shapes the systemic immune response to PD-1 checkpoint blockade","volume":"12","author":"Khan","year":"2021","journal-title":"Nat Commun"},{"key":"2025100300562845000_13.1.e008876.32","doi-asserted-by":"publisher","DOI":"10.2337\/db18-1471-P"},{"key":"2025100300562845000_13.1.e008876.33","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1922867117"},{"key":"2025100300562845000_13.1.e008876.34","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1182\/blood-2022-166322","article-title":"Patients with Deleterious Germline Variants in STXBP2 Develop Toxicity after CAR-T Cell Therapy with Axicabtagene Ciloleucel","volume":"140","author":"Leick","year":"2022","journal-title":"Blood"},{"key":"2025100300562845000_13.1.e008876.35","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-000617","article-title":"Oncogenic states dictate the prognostic and predictive connotations of intratumoral immune response","volume":"8","author":"Roelands","year":"2020","journal-title":"J Immunother Cancer"},{"key":"2025100300562845000_13.1.e008876.36","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1038\/s41591-023-02324-5","article-title":"An integrated tumor, immune and microbiome atlas of colon cancer","volume":"29","author":"Roelands","year":"2023","journal-title":"Nat Med"},{"key":"2025100300562845000_13.1.e008876.37","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s40425-018-0355-5","article-title":"Immune oncology, immune responsiveness and the theory of everything","volume":"6","author":"Turan","year":"2018","journal-title":"j immunotherapy cancer"},{"key":"2025100300562845000_13.1.e008876.38","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1038\/s41416-020-01145-4","article-title":"A balance score between immune stimulatory and suppressive microenvironments identifies mediators of tumour immunity and predicts pan-cancer survival","volume":"124","author":"Turan","year":"2021","journal-title":"Br J Cancer"},{"key":"2025100300562845000_13.1.e008876.39","doi-asserted-by":"publisher","DOI":"10.1038\/s41588-023-01557-x"},{"key":"2025100300562845000_13.1.e008876.40","doi-asserted-by":"crossref","DOI":"10.1186\/s12967-024-05043-8","article-title":"Shifting the paradigm: engaging multicellular networks for cancer therapy","volume":"22","author":"Hu","year":"2024","journal-title":"J Transl Med"},{"key":"2025100300562845000_13.1.e008876.41","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2019-000363","article-title":"High-dimensional immune-profiling in cancer: implications for immunotherapy","volume":"8","author":"Chuah","year":"2020","journal-title":"J Immunother Cancer"},{"key":"2025100300562845000_13.1.e008876.42","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2024.01.027"},{"key":"2025100300562845000_13.1.e008876.43","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2018.1538436","article-title":"Genomic and transcriptional Profiling of tumor infiltrated CD8+ T cells revealed functional heterogeneity of antitumor immunity in hepatocellular carcinoma","volume":"8","author":"Li","year":"2019","journal-title":"Oncoimmunology"},{"key":"2025100300562845000_13.1.e008876.44","article-title":"Profiling of immune features to predict immunotherapy efficacy","volume":"3","author":"Ye","year":"2022","journal-title":"Innov Camb"},{"key":"2025100300562845000_13.1.e008876.45","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20201574","article-title":"The current landscape of single-cell transcriptomics for cancer immunotherapy","volume":"218","author":"Guruprasad","year":"2021","journal-title":"J Exp Med"},{"key":"2025100300562845000_13.1.e008876.46","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12092572","article-title":"Transcriptional Spatial Profiling of Cancer Tissues in the Era of Immunotherapy: The Potential and Promise","volume":"12","author":"Nerurkar","year":"2020","journal-title":"Cancers (Basel)"},{"key":"2025100300562845000_13.1.e008876.47","first-page":"3581","article-title":"Prospective molecular profiling of melanoma metastases suggests classifiers of immune responsiveness","volume":"62","author":"Wang","year":"2002","journal-title":"Cancer Res"},{"key":"2025100300562845000_13.1.e008876.48","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2008.03.002"},{"key":"2025100300562845000_13.1.e008876.49","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.49.2157"},{"key":"2025100300562845000_13.1.e008876.50","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2016.1253654","article-title":"Identification of genetic determinants of breast cancer immune phenotypes by integrative genome-scale analysis","volume":"6","author":"Hendrickx","year":"2017","journal-title":"Oncoimmunology"},{"key":"2025100300562845000_13.1.e008876.51","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1038\/s41416-018-0309-1","article-title":"The immunologic constant of rejection classification refines the prognostic value of conventional prognostic signatures in breast cancer","volume":"119","author":"Bertucci","year":"2018","journal-title":"Br J Cancer"},{"key":"2025100300562845000_13.1.e008876.52","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003687","article-title":"Immunologic constant of rejection signature is prognostic in soft-tissue sarcoma and refines the CINSARC signature","volume":"10","author":"Bertucci","year":"2022","journal-title":"J Immunother Cancer"},{"key":"2025100300562845000_13.1.e008876.53","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2013.07.008"},{"key":"2025100300562845000_13.1.e008876.54","doi-asserted-by":"crossref","DOI":"10.1186\/s12967-023-04463-2","article-title":"Immunologic constant of rejection as a predictive biomarker of immune checkpoint inhibitors efficacy in non-small cell lung cancer","volume":"21","author":"Mogenet","year":"2023","journal-title":"J Transl Med"},{"key":"2025100300562845000_13.1.e008876.55","doi-asserted-by":"crossref","DOI":"10.1126\/science.aar3593","article-title":"Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapy","volume":"362","author":"Cristescu","year":"2018","journal-title":"Science"},{"key":"2025100300562845000_13.1.e008876.56","doi-asserted-by":"crossref","DOI":"10.1186\/s12967-023-04017-6","article-title":"Immunogenic cell death in cancer: concept and therapeutic implications","volume":"21","author":"Galluzzi","year":"2023","journal-title":"J Transl Med"},{"key":"2025100300562845000_13.1.e008876.57","doi-asserted-by":"crossref","DOI":"10.1186\/s40170-021-00272-7","article-title":"Robust metabolic transcriptional components in 34,494 patient-derived cancer-related samples and cell lines","volume":"9","author":"Leeuwenburgh","year":"2021","journal-title":"Cancer Metab"},{"key":"2025100300562845000_13.1.e008876.58","doi-asserted-by":"crossref","DOI":"10.15252\/embj.2019104063","article-title":"Stromal cell diversity associated with immune evasion in human triple-negative breast cancer","volume":"39","author":"Wu","year":"2020","journal-title":"EMBO J"},{"key":"2025100300562845000_13.1.e008876.59","doi-asserted-by":"crossref","DOI":"10.1126\/science.abe6474","article-title":"Pan-cancer single-cell landscape of tumor-infiltrating T cells","volume":"374","author":"Zheng","year":"2021","journal-title":"Science"},{"key":"2025100300562845000_13.1.e008876.60","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.3389\/fimmu.2020.01678","article-title":"Identification of an Immune Signature Predicting Prognosis Risk and Lymphocyte Infiltration in Colon Cancer","volume":"11","author":"Li","year":"2020","journal-title":"Front Immunol"},{"key":"2025100300562845000_13.1.e008876.61","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.18632\/oncotarget.26773","article-title":"A global immune gene expression signature for human cancers","volume":"10","author":"Liu","year":"2019","journal-title":"Oncotarget"},{"key":"2025100300562845000_13.1.e008876.62","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-18-0500"},{"key":"2025100300562845000_13.1.e008876.63","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21051850","article-title":"Transcriptional Profiling of Advanced Urothelial Cancer Predicts Prognosis and Response to Immunotherapy","volume":"21","author":"Baek","year":"2020","journal-title":"Int J Mol Sci"},{"key":"2025100300562845000_13.1.e008876.64","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-57218-9"},{"key":"2025100300562845000_13.1.e008876.65","doi-asserted-by":"publisher","DOI":"10.1038\/S41568-020-0285-7"},{"key":"2025100300562845000_13.1.e008876.66","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.00490","article-title":"Single-Cell Approaches to Profile the Response to Immune Checkpoint Inhibitors","volume":"11","author":"Gibellini","year":"2020","journal-title":"Front Immunol"},{"key":"2025100300562845000_13.1.e008876.67","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1002\/JLB.MR0618-241RR","article-title":"OMIC signatures to understand cancer immunosurveillance and immunoediting: Melanoma and immune cells interplay in immunotherapy","volume":"105","author":"Le\u00f3n-Letelier","year":"2019","journal-title":"J Leukoc Biol"},{"key":"2025100300562845000_13.1.e008876.68","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-019-13880-1","article-title":"Clonal kinetics and single-cell transcriptional profiling of CAR-T cells in patients undergoing CD19 CAR-T immunotherapy","volume":"11","author":"Sheih","year":"2020","journal-title":"Nat Commun"},{"key":"2025100300562845000_13.1.e008876.69","doi-asserted-by":"publisher","DOI":"10.1038\/s41588-021-00911-1"},{"key":"2025100300562845000_13.1.e008876.70","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-21-1357"},{"key":"2025100300562845000_13.1.e008876.71","doi-asserted-by":"publisher","DOI":"10.1038\/s41588-022-01134-8"},{"key":"2025100300562845000_13.1.e008876.72","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003890","article-title":"Spatial transcriptomics of macrophage infiltration in non-small cell lung cancer reveals determinants of sensitivity and resistance to anti-PD1\/PD-L1 antibodies","volume":"10","author":"Larroquette","year":"2022","journal-title":"J Immunother Cancer"},{"key":"2025100300562845000_13.1.e008876.73","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-4142"},{"key":"2025100300562845000_13.1.e008876.74","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-17-2542"},{"key":"2025100300562845000_13.1.e008876.75","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-0309"},{"key":"2025100300562845000_13.1.e008876.76","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1172\/jci.insight.121932","article-title":"Spatial and phenotypic immune profiling of metastatic colon cancer","volume":"3","author":"Lazarus","year":"2018","journal-title":"JCI Insight"},{"key":"2025100300562845000_13.1.e008876.77","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1093\/neuonc\/noy035","article-title":"Multiplexed immunofluorescence reveals potential PD-1\/PD-L1 pathway vulnerabilities in craniopharyngioma","volume":"20","author":"Coy","year":"2018","journal-title":"Neuro Oncol"},{"key":"2025100300562845000_13.1.e008876.78","doi-asserted-by":"publisher","DOI":"10.1172\/JCI96313"},{"key":"2025100300562845000_13.1.e008876.79","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2018.08.039"},{"key":"2025100300562845000_13.1.e008876.80","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/978-3-030-38862-1_6","article-title":"The Paradox of Cancer Immune Exclusion: Immune Oncology Next Frontier","volume":"180","author":"Pai","year":"2020","journal-title":"Cancer Treat Res"},{"key":"2025100300562845000_13.1.e008876.81","doi-asserted-by":"crossref","DOI":"10.1186\/s12967-020-02667-4","article-title":"Hypoxia and the phenomenon of immune exclusion","volume":"19","author":"Pietrobon","year":"2021","journal-title":"J Transl Med"},{"key":"2025100300562845000_13.1.e008876.82","doi-asserted-by":"publisher","DOI":"10.1172\/JCI91190"},{"key":"2025100300562845000_13.1.e008876.83","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.78.2276"},{"key":"2025100300562845000_13.1.e008876.84","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003026","article-title":"Influence of tumor mutational burden, inflammatory gene expression profile, and PD-L1 expression on response to pembrolizumab in head and neck squamous cell carcinoma","volume":"10","author":"Haddad","year":"2022","journal-title":"J Immunother Cancer"},{"key":"2025100300562845000_13.1.e008876.85","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1158\/1078-0432.CCR-21-3329","article-title":"Transcriptomic Determinants of Response to Pembrolizumab Monotherapy across Solid Tumor Types","volume":"28","author":"Cristescu","year":"2022","journal-title":"Clin Cancer Res"},{"key":"2025100300562845000_13.1.e008876.86","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-01211-7"},{"key":"2025100300562845000_13.1.e008876.87","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02754-1"},{"key":"2025100300562845000_13.1.e008876.88","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2021.01.002"},{"key":"2025100300562845000_13.1.e008876.89","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1200\/PO.20.00371","article-title":"Pursuing Better Biomarkers for Immunotherapy Response in Cancer Through a Crowdsourced Data Challenge","volume":"5","author":"Vincent","year":"2021","journal-title":"JCO Precis Oncol"},{"key":"2025100300562845000_13.1.e008876.90","unstructured":"Mason M , et al . A community challenge to predict clinical outcomes after immune checkpoint blockade in non-small cell lung cancer. bioRxiv [Preprint] 2022."},{"key":"2025100300562845000_13.1.e008876.91","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1002\/path.5898","article-title":"Artificial intelligence to identify genetic alterations in conventional histopathology","volume":"257","author":"Cifci","year":"2022","journal-title":"J Pathol"},{"key":"2025100300562845000_13.1.e008876.92","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1038\/s43018-020-0087-6","article-title":"Pan-cancer image-based detection of clinically actionable genetic alterations","volume":"1","author":"Kather","year":"2020","journal-title":"Nat Cancer"},{"key":"2025100300562845000_13.1.e008876.93","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1038\/s43018-020-0085-8","article-title":"Pan-cancer computational histopathology reveals mutations, tumor composition and prognosis","volume":"1","author":"Fu","year":"2020","journal-title":"Nat Cancer"},{"key":"2025100300562845000_13.1.e008876.94","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-020-17678-4","article-title":"A deep learning model to predict RNA-Seq expression of tumours from whole slide images","volume":"11","author":"Schmauch","year":"2020","journal-title":"Nat Commun"},{"key":"2025100300562845000_13.1.e008876.95","doi-asserted-by":"crossref","DOI":"10.1016\/j.jhepr.2022.100443","article-title":"Artificial intelligence in liver diseases: Improving diagnostics, prognostics and response prediction","volume":"4","author":"Nam","year":"2022","journal-title":"JHEP Rep"},{"key":"2025100300562845000_13.1.e008876.96","doi-asserted-by":"crossref","DOI":"10.3390\/nu13072217","article-title":"Diet, Microbiome, and Cancer Immunotherapy-A Comprehensive Review","volume":"13","author":"Szczyrek","year":"2021","journal-title":"Nutrients"},{"key":"2025100300562845000_13.1.e008876.97","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2020.08.013"},{"key":"2025100300562845000_13.1.e008876.98","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1146\/annurev-nutr-062320-115937","article-title":"Obesity Dysregulates the Immune Response to Influenza Infection and Vaccination Through Metabolic and Inflammatory Mechanisms","volume":"42","author":"Shaikh","year":"2022","journal-title":"Annu Rev Nutr"},{"key":"2025100300562845000_13.1.e008876.99","doi-asserted-by":"publisher","DOI":"10.1126\/science.aad1329"},{"key":"2025100300562845000_13.1.e008876.100","doi-asserted-by":"publisher","DOI":"10.1126\/science.aac4255"},{"key":"2025100300562845000_13.1.e008876.101","doi-asserted-by":"publisher","DOI":"10.1126\/science.1240527"},{"key":"2025100300562845000_13.1.e008876.102","doi-asserted-by":"publisher","DOI":"10.1126\/science.1240537"},{"key":"2025100300562845000_13.1.e008876.103","doi-asserted-by":"publisher","DOI":"10.1016\/j.neo.2017.08.004"},{"key":"2025100300562845000_13.1.e008876.104","doi-asserted-by":"publisher","DOI":"10.1126\/science.aan4236"},{"key":"2025100300562845000_13.1.e008876.105","doi-asserted-by":"publisher","DOI":"10.1126\/science.aao3290"},{"key":"2025100300562845000_13.1.e008876.106","doi-asserted-by":"publisher","DOI":"10.1126\/science.aan3706"},{"key":"2025100300562845000_13.1.e008876.107","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2018-317220"},{"key":"2025100300562845000_13.1.e008876.108","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-01695-5"},{"key":"2025100300562845000_13.1.e008876.109","doi-asserted-by":"publisher","DOI":"10.1126\/science.abf3363"},{"key":"2025100300562845000_13.1.e008876.110","doi-asserted-by":"publisher","DOI":"10.1126\/science.abb5920"},{"key":"2025100300562845000_13.1.e008876.111","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-01694-6"},{"key":"2025100300562845000_13.1.e008876.112","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02453-x"},{"key":"2025100300562845000_13.1.e008876.113","doi-asserted-by":"crossref","DOI":"10.1186\/s40168-019-0704-8","article-title":"Macronutrient metabolism by the human gut microbiome: major fermentation by-products and their impact on host health","volume":"7","author":"Oliphant","year":"2019","journal-title":"Microbiome"},{"key":"2025100300562845000_13.1.e008876.114","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2016.10.043"},{"key":"2025100300562845000_13.1.e008876.115","doi-asserted-by":"crossref","DOI":"10.1038\/cti.2016.17","article-title":"Regulation of immune cell function by short-chain fatty acids","volume":"5","author":"Corr\u00eaa-Oliveira","year":"2016","journal-title":"Clin Transl Immunology"},{"key":"2025100300562845000_13.1.e008876.116","doi-asserted-by":"publisher","DOI":"10.1126\/science.aaz7015"},{"key":"2025100300562845000_13.1.e008876.117","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2021.09.019"},{"key":"2025100300562845000_13.1.e008876.118","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2016.06.005"},{"key":"2025100300562845000_13.1.e008876.119","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/s43018-019-0007-9","article-title":"Short-term starvation reduces IGF-1 levels to sensitize lung tumors to PD-1 immune checkpoint blockade","volume":"1","author":"Ajona","year":"2020","journal-title":"Nat Cancer"},{"key":"2025100300562845000_13.1.e008876.120","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.145207","article-title":"Ketogenic diet and ketone bodies enhance the anticancer effects of PD-1 blockade","volume":"6","author":"Ferrere","year":"2021","journal-title":"JCI Insight"},{"key":"2025100300562845000_13.1.e008876.121","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2021.662591","article-title":"The Potential Roles of Very Low Calorie, Very Low Calorie Ketogenic Diets and Very Low Carbohydrate Diets on the Gut Microbiota Composition","volume":"12","author":"Rondanelli","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2025100300562845000_13.1.e008876.122","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-21-0030"},{"key":"2025100300562845000_13.1.e008876.123","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMsr1606602"},{"key":"2025100300562845000_13.1.e008876.124","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(18)30078-0"},{"key":"2025100300562845000_13.1.e008876.125","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.0448","article-title":"Outcomes Among Patients With or Without Obesity and With Cancer Following Treatment With Immune Checkpoint Blockade","volume":"5","author":"Yoo","year":"2022","journal-title":"JAMA Netw Open"},{"key":"2025100300562845000_13.1.e008876.126","doi-asserted-by":"crossref","DOI":"10.1186\/s12967-020-02404-x","article-title":"Association between body mass index and survival outcomes for cancer patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis","volume":"18","author":"An","year":"2020","journal-title":"J Transl Med"},{"key":"2025100300562845000_13.1.e008876.127","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.3390\/cancers12061583","article-title":"Obesity and the Impact on Cutaneous Melanoma: Friend or Foe?","volume":"12","author":"Smith","year":"2020","journal-title":"Cancers (Basel)"},{"key":"2025100300562845000_13.1.e008876.128","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1158\/1078-0432.CCR-22-2661","article-title":"Obesity Is Associated with Altered Tumor Metabolism in Metastatic Melanoma","volume":"29","author":"Hahn","year":"2023","journal-title":"Clin Cancer Res"},{"key":"2025100300562845000_13.1.e008876.129","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1001\/jamaoncol.2022.5409","article-title":"Association of Body Mass Index With the Safety Profile of Nivolumab With or Without Ipilimumab","volume":"9","author":"McQuade","year":"2023","journal-title":"JAMA Oncol"},{"key":"2025100300562845000_13.1.e008876.130","doi-asserted-by":"publisher","DOI":"10.1200\/jco.22.00687"},{"key":"2025100300562845000_13.1.e008876.131","doi-asserted-by":"publisher","DOI":"10.1249\/mss.0000000000002116"},{"key":"2025100300562845000_13.1.e008876.132","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djv040","article-title":"Modulation of murine breast tumor vascularity, hypoxia and chemotherapeutic response by exercise","volume":"107","author":"Betof","year":"2015","journal-title":"J Natl Cancer Inst"},{"key":"2025100300562845000_13.1.e008876.133","doi-asserted-by":"crossref","first-page":"65429","DOI":"10.18632\/oncotarget.11748","article-title":"Tumor vessel normalization after aerobic exercise enhances chemotherapeutic efficacy","volume":"7","author":"Schadler","year":"2016","journal-title":"Oncotarget"},{"key":"2025100300562845000_13.1.e008876.134","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.semradonc.2018.10.001","article-title":"Exercise as Adjunct Therapy in Cancer","volume":"29","author":"Ashcraft","year":"2019","journal-title":"Semin Radiat Oncol"},{"key":"2025100300562845000_13.1.e008876.135","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2016.01.011"},{"key":"2025100300562845000_13.1.e008876.136","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.imlet.2021.08.005","article-title":"Effects of exercise and anti-PD-1 on the tumour microenvironment","volume":"239","author":"Buss","year":"2021","journal-title":"Immunol Lett"},{"key":"2025100300562845000_13.1.e008876.137","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2022.05.006"},{"key":"2025100300562845000_13.1.e008876.138","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.23567"},{"key":"2025100300562845000_13.1.e008876.139","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001361","article-title":"Integrated analysis of concomitant medications and oncological outcomes from PD-1\/PD-L1 checkpoint inhibitors in clinical practice","volume":"8","author":"Cortellini","year":"2020","journal-title":"J Immunother Cancer"},{"key":"2025100300562845000_13.1.e008876.140","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2021.11.002"},{"key":"2025100300562845000_13.1.e008876.141","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.79.0006"},{"key":"2025100300562845000_13.1.e008876.142","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1038\/s41586-022-04567-7","article-title":"Environmental factors shaping the gut microbiome in a Dutch population","volume":"604","author":"Gacesa","year":"2022","journal-title":"Nature New Biol"},{"key":"2025100300562845000_13.1.e008876.143","doi-asserted-by":"crossref","DOI":"10.1186\/s13045-021-01056-8","article-title":"Next generation of immune checkpoint inhibitors and beyond","volume":"14","author":"Marin-Acevedo","year":"2021","journal-title":"J Hematol Oncol"},{"key":"2025100300562845000_13.1.e008876.144","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1002\/smll.201002330","article-title":"Enhanced field emission and improved supercapacitor obtained from plasma-modified bucky paper","volume":"7","author":"Roy","year":"2011","journal-title":"Small"},{"key":"2025100300562845000_13.1.e008876.145","doi-asserted-by":"crossref","DOI":"10.1186\/s12943-019-1091-2","article-title":"Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4","volume":"18","author":"Qin","year":"2019","journal-title":"Mol Cancer"},{"key":"2025100300562845000_13.1.e008876.146","doi-asserted-by":"crossref","first-page":"1121285","DOI":"10.3389\/fimmu.2023.1121285","article-title":"Diversity of immune checkpoints in cancer immunotherapy","volume":"14","author":"Guo","year":"2023","journal-title":"Front Immunol"},{"key":"2025100300562845000_13.1.e008876.147","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2021.09.020"},{"key":"2025100300562845000_13.1.e008876.148","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2019-000398","article-title":"Defining tumor resistance to PD-1 pathway blockade: recommendations from the first meeting of the SITC Immunotherapy Resistance Taskforce","volume":"8","author":"Kluger","year":"2020","journal-title":"J Immunother Cancer"},{"key":"2025100300562845000_13.1.e008876.149","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2020.00672","article-title":"Resistance Mechanisms of Anti-PD1\/PDL1 Therapy in Solid Tumors","volume":"8","author":"Lei","year":"2020","journal-title":"Front Cell Dev Biol"},{"key":"2025100300562845000_13.1.e008876.150","doi-asserted-by":"crossref","DOI":"10.1186\/s40425-019-0602-4","article-title":"Toward a comprehensive view of cancer immune responsiveness: a synopsis from the SITC workshop","volume":"7","author":"Bedognetti","year":"2019","journal-title":"J Immunother Cancer"},{"key":"2025100300562845000_13.1.e008876.151","doi-asserted-by":"publisher","DOI":"10.1126\/science.1203486"},{"key":"2025100300562845000_13.1.e008876.152","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-019-0116-x"},{"key":"2025100300562845000_13.1.e008876.153","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/nature12477","article-title":"Signatures of mutational processes in human cancer","volume":"500","author":"Alexandrov","year":"2013","journal-title":"Nature New Biol"},{"key":"2025100300562845000_13.1.e008876.154","doi-asserted-by":"publisher","DOI":"10.1126\/science.aan6733"},{"key":"2025100300562845000_13.1.e008876.155","doi-asserted-by":"crossref","first-page":"e275","DOI":"10.1200\/EDBK_280571","article-title":"Biomarkers in Precision Cancer Immunotherapy: Promise and Challenges","volume":"40","author":"McKean","year":"2020","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"2025100300562845000_13.1.e008876.156","doi-asserted-by":"publisher","DOI":"10.1126\/science.aaf1490"},{"key":"2025100300562845000_13.1.e008876.157","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2020.1868130","article-title":"Immune-based mutation classification enables neoantigen prioritization and immune feature discovery in cancer immunotherapy","volume":"10","author":"Bai","year":"2021","journal-title":"Oncoimmunology"},{"key":"2025100300562845000_13.1.e008876.158","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2020.09.015"},{"key":"2025100300562845000_13.1.e008876.159","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1038\/nature10755","article-title":"Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting","volume":"482","author":"Matsushita","year":"2012","journal-title":"Nature New Biol"},{"key":"2025100300562845000_13.1.e008876.160","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2018.09.018"},{"key":"2025100300562845000_13.1.e008876.161","doi-asserted-by":"publisher","DOI":"10.1038\/s41588-023-01313-1"},{"key":"2025100300562845000_13.1.e008876.162","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-023-40994-4","article-title":"Guadecitabine plus ipilimumab in unresectable melanoma: five-year follow-up and integrated multi-omic analysis in the phase 1b NIBIT-M4 trial","volume":"14","author":"Noviello","year":"2023","journal-title":"Nat Commun"},{"key":"2025100300562845000_13.1.e008876.163","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2019.02.008"},{"key":"2025100300562845000_13.1.e008876.164","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-3101"},{"key":"2025100300562845000_13.1.e008876.165","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2016.02.065"},{"key":"2025100300562845000_13.1.e008876.166","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2017.02.001"},{"key":"2025100300562845000_13.1.e008876.167","doi-asserted-by":"publisher","DOI":"10.1038\/nature14404"},{"key":"2025100300562845000_13.1.e008876.168","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-16-1439"},{"key":"2025100300562845000_13.1.e008876.169","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-017-01062-w","article-title":"Resistance to checkpoint blockade therapy through inactivation of antigen presentation","volume":"8","author":"Sade-Feldman","year":"2017","journal-title":"Nat Commun"},{"key":"2025100300562845000_13.1.e008876.170","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2103695"},{"key":"2025100300562845000_13.1.e008876.171","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12123802","article-title":"Characteristics of the Tumor Microenvironment That Influence Immune Cell Functions: Hypoxia, Oxidative Stress, Metabolic Alterations","volume":"12","author":"Augustin","year":"2020","journal-title":"Cancers (Basel)"},{"key":"2025100300562845000_13.1.e008876.172","doi-asserted-by":"publisher","DOI":"10.1016\/bs.acr.2019.03.003"},{"key":"2025100300562845000_13.1.e008876.173","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2016.1261779","article-title":"Adaptive resistance to anti-PD1 therapy by Tim-3 upregulation is mediated by the PI3K-Akt pathway in head and neck cancer","volume":"6","author":"Shayan","year":"2017","journal-title":"Oncoimmunology"},{"key":"2025100300562845000_13.1.e008876.174","doi-asserted-by":"publisher","DOI":"10.1111\/imr.12519"},{"key":"2025100300562845000_13.1.e008876.175","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1038\/s41591-022-01829-9","article-title":"Sotigalimab and\/or nivolumab with chemotherapy in first-line metastatic pancreatic cancer: clinical and immunologic analyses from the randomized phase 2 PRINCE trial","volume":"28","author":"Padr\u00f3n","year":"2022","journal-title":"N Med"},{"key":"2025100300562845000_13.1.e008876.176","doi-asserted-by":"crossref","DOI":"10.1186\/s12943-020-01234-1","article-title":"Regulatory T cells in tumor microenvironment: new mechanisms, potential therapeutic strategies and future prospects","volume":"19","author":"Li","year":"2020","journal-title":"Mol Cancer"},{"key":"2025100300562845000_13.1.e008876.177","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.00783","article-title":"Targeting Myeloid-Derived Suppressor Cell, a Promising Strategy to Overcome Resistance to Immune Checkpoint Inhibitors","volume":"11","author":"Hou","year":"2020","journal-title":"Front Immunol"},{"key":"2025100300562845000_13.1.e008876.178","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.874589","article-title":"Tumor-Associated Macrophages Regulate PD-1\/PD-L1 Immunosuppression","volume":"13","author":"Pu","year":"2022","journal-title":"Front Immunol"},{"key":"2025100300562845000_13.1.e008876.179","doi-asserted-by":"crossref","DOI":"10.1038\/s41392-020-00377-3","article-title":"Reprogramming immunosuppressive myeloid cells by activated T cells promotes the response to anti-PD-1 therapy in colorectal cancer","volume":"6","author":"Chen","year":"2021","journal-title":"Signal Transduct Target Ther"},{"key":"2025100300562845000_13.1.e008876.180","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.jconrel.2020.02.011","article-title":"Remodeling tumor immune microenvironment via targeted blockade of PI3K-\u03b3 and CSF-1\/CSF-1R pathways in tumor associated macrophages for pancreatic cancer therapy","volume":"321","author":"Li","year":"2020","journal-title":"J Control Release"},{"key":"2025100300562845000_13.1.e008876.181","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.01680","article-title":"The New Era of Cancer Immunotherapy: Targeting Myeloid-Derived Suppressor Cells to Overcome Immune Evasion","volume":"11","author":"De Cicco","year":"2020","journal-title":"Front Immunol"},{"key":"2025100300562845000_13.1.e008876.182","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2022.05.004"},{"key":"2025100300562845000_13.1.e008876.183","doi-asserted-by":"crossref","DOI":"10.1016\/j.ccell.2021.04.016","article-title":"The loss of RNA N6-adenosine methyltransferase Mettl14 in tumor-associated macrophages promotes CD8+ T cell dysfunction and tumor growth","volume":"39","author":"Dong","year":"2021","journal-title":"Cancer Cell"},{"key":"2025100300562845000_13.1.e008876.184","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2022.02.021"},{"key":"2025100300562845000_13.1.e008876.185","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2020.07.013"},{"key":"2025100300562845000_13.1.e008876.186","doi-asserted-by":"crossref","DOI":"10.1016\/j.iotech.2022.100070","article-title":"CD47-SIRP\u03b1-targeted therapeutics: status and prospects","volume":"13","author":"Maute","year":"2022","journal-title":"Immunooncol Technol"},{"key":"2025100300562845000_13.1.e008876.187","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.02018"},{"key":"2025100300562845000_13.1.e008876.188","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1807315"},{"key":"2025100300562845000_13.1.e008876.189","first-page":"18","article-title":"A phase Ib study of the anti-CD47 antibody magrolimab with the PD-L1 inhibitor avelumab (A) in solid tumor (ST) and ovarian cancer (OC) patients","volume":"38","author":"Lakhani","year":"2020","journal-title":"J C O"},{"key":"2025100300562845000_13.1.e008876.190","doi-asserted-by":"crossref","DOI":"10.1186\/s13045-019-0721-x","article-title":"Activating cGAS-STING pathway for the optimal effect of cancer immunotherapy","volume":"12","author":"Li","year":"2019","journal-title":"J Hematol Oncol"},{"key":"2025100300562845000_13.1.e008876.191","doi-asserted-by":"crossref","first-page":"11","DOI":"10.3390\/cancers13112695","article-title":"STING Agonists as Cancer Therapeutics","volume":"13","author":"Amouzegar","year":"2021","journal-title":"Cancers (Basel)"},{"key":"2025100300562845000_13.1.e008876.192","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-1963"},{"key":"2025100300562845000_13.1.e008876.193","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2018.00878","article-title":"The Role of Toll-Like Receptor in Inflammation and Tumor Immunity","volume":"9","author":"Cen","year":"2018","journal-title":"Front Pharmacol"},{"key":"2025100300562845000_13.1.e008876.194","doi-asserted-by":"crossref","unstructured":"Milhem M , Zakharia Y , Davar D , et al . 304\u2005Intratumoral injection of cmp-001, a toll-like receptor 9 (tlr9) agonist, in combination with pembrolizumab reversed programmed death receptor 1 (pd-1) blockade resistance in advanced melanoma. 35th Anniversary Annual Meeting (SITC 2020); November 2020 doi:10.1136\/jitc-2020-SITC2020.0304","DOI":"10.1136\/jitc-2020-SITC2020.0304"},{"key":"2025100300562845000_13.1.e008876.195","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2021.05.013"},{"key":"2025100300562845000_13.1.e008876.196","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.124989","article-title":"Tumor cell oxidative metabolism as a barrier to PD-1 blockade immunotherapy in melanoma","volume":"4","author":"Najjar","year":"2019","journal-title":"JCI Insight"},{"key":"2025100300562845000_13.1.e008876.197","doi-asserted-by":"publisher","DOI":"10.1038\/s12276-020-00500-y"},{"key":"2025100300562845000_13.1.e008876.198","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.00221"},{"key":"2025100300562845000_13.1.e008876.199","doi-asserted-by":"crossref","unstructured":"Shaikh S , Zang Y , Wang H , et al . 435\u2005A phase ii trial of nivolumab plus axitinib in patients with anti-pd1 refractory advanced melanoma. Journal for ImmunoTherapy of Cancer; November 2020 doi:10.1136\/jitc-2020-SITC2020.0435","DOI":"10.1136\/jitc-2020-SITC2020.0435"},{"key":"2025100300562845000_13.1.e008876.200","doi-asserted-by":"crossref","DOI":"10.1186\/s40425-018-0360-8","article-title":"Targeting adenosine for cancer immunotherapy","volume":"6","author":"Leone","year":"2018","journal-title":"J Immunother Cancer"},{"key":"2025100300562845000_13.1.e008876.201","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-004089","article-title":"Next steps for clinical translation of adenosine pathway inhibition in cancer immunotherapy","volume":"10","author":"Augustin","year":"2022","journal-title":"J Immunother Cancer"},{"key":"2025100300562845000_13.1.e008876.202","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21165604"},{"key":"2025100300562845000_13.1.e008876.203","doi-asserted-by":"publisher","DOI":"10.1093\/intimm\/dxx073"},{"key":"2025100300562845000_13.1.e008876.204","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.586907","article-title":"Systemic CD4 Immunity as a Key Contributor to PD-L1\/PD-1 Blockade Immunotherapy Efficacy","volume":"11","author":"Zuazo","year":"2020","journal-title":"Front Immunol"},{"key":"2025100300562845000_13.1.e008876.205","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01462-y"},{"key":"2025100300562845000_13.1.e008876.206","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1038\/s41586-021-03704-y","article-title":"Phenotype, specificity and avidity of antitumour CD8+ T cells in melanoma","volume":"596","author":"Oliveira","year":"2021","journal-title":"Nature New Biol"},{"key":"2025100300562845000_13.1.e008876.207","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1707447"},{"key":"2025100300562845000_13.1.e008876.208","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1708566"},{"key":"2025100300562845000_13.1.e008876.209","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1914347"},{"key":"2025100300562845000_13.1.e008876.210","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00591-X"},{"key":"2025100300562845000_13.1.e008876.211","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1709866"},{"key":"2025100300562845000_13.1.e008876.212","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1709919"},{"key":"2025100300562845000_13.1.e008876.213","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1002\/ajh.25951","article-title":"Commercial anti\u2010CD19 CAR T cell therapy for patients with relapsed\/refractory aggressive B cell lymphoma in a European center","volume":"95","author":"Sesques","year":"2020","journal-title":"Am J Hematol"},{"key":"2025100300562845000_13.1.e008876.214","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2019-124750","article-title":"Post-Marketing Use Outcomes of an Anti-CD19 Chimeric Antigen Receptor (CAR) T Cell Therapy, Axicabtagene Ciloleucel (Axi-Cel), for the Treatment of Large B Cell Lymphoma (LBCL) in the United States (US)","volume":"134","author":"Pasquini","year":"2019","journal-title":"Blood"},{"key":"2025100300562845000_13.1.e008876.215","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2019-124177","article-title":"Real-World Data of High-Grade Lymphoma Patients Treated with CD19 CAR-T in England","volume":"134","author":"Kuhnl","year":"2019","journal-title":"Blood"},{"key":"2025100300562845000_13.1.e008876.216","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020003092"},{"key":"2025100300562845000_13.1.e008876.217","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2019-130983","article-title":"Tisagenlecleucel Chimeric Antigen Receptor (CAR) T-Cell Therapy for Adults with Diffuse Large B-Cell Lymphoma (DLBCL): Real World Experience from the Center for International Blood & Marrow Transplant Research (CIBMTR) Cellular Therapy (CT) Registry","volume":"134","author":"Jaglowski","year":"2019","journal-title":"Blood"},{"key":"2025100300562845000_13.1.e008876.218","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1182\/blood-2020-134472","article-title":"Disease Burden Impacts Outcomes in Pediatric and Young Adult B-Cell Acute Lymphoblastic Leukemia after Commercial Tisagenlecleucel: Results from the Pediatric Real World CAR Consortium (PRWCC)","volume":"136","author":"Schultz","year":"2020","journal-title":"Blood"},{"key":"2025100300562845000_13.1.e008876.219","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0010-1"},{"key":"2025100300562845000_13.1.e008876.220","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-05-286286"},{"key":"2025100300562845000_13.1.e008876.221","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020002394"},{"key":"2025100300562845000_13.1.e008876.222","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1407222"},{"key":"2025100300562845000_13.1.e008876.223","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.780442","article-title":"T Cell Fitness and Autologous CAR T Cell Therapy in Haematologic Malignancy","volume":"12","author":"Mehta","year":"2021","journal-title":"Front Immunol"},{"key":"2025100300562845000_13.1.e008876.224","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1111\/bjh.17191","article-title":"CAR-T TREK through the lymphoma universe, to boldly go where no other therapy has gone before","volume":"193","author":"Ghilardi","year":"2021","journal-title":"Br J Haematol"},{"key":"2025100300562845000_13.1.e008876.225","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1080\/13696998.2018.1529674","article-title":"Cost-effectiveness of axicabtagene ciloleucel for adult patients with relapsed or refractory large B-cell lymphoma in the United States","volume":"21","author":"Roth","year":"2018","journal-title":"J Med Econ"},{"key":"2025100300562845000_13.1.e008876.226","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.02079"},{"key":"2025100300562845000_13.1.e008876.227","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/s41573-019-0051-2","article-title":"\u201cOff-the-shelf\u201d allogeneic CAR T cells: development and challenges","volume":"19","author":"Depil","year":"2020","journal-title":"Nat Rev Drug Discov"},{"key":"2025100300562845000_13.1.e008876.228","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1038\/s41551-021-00842-6","article-title":"Rapid manufacturing of non-activated potent CAR T cells","volume":"6","author":"Ghassemi","year":"2022","journal-title":"Nat Biomed Eng"},{"key":"2025100300562845000_13.1.e008876.229","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2030164"},{"key":"2025100300562845000_13.1.e008876.230","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1038\/s41591-021-01436-0","article-title":"CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial","volume":"27","author":"Spiegel","year":"2021","journal-title":"Nat Med"},{"key":"2025100300562845000_13.1.e008876.231","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2019-126218","article-title":"CD19-Loss with Preservation of Other B Cell Lineage Features in Patients with Large B Cell Lymphoma Who Relapsed Post-Axi-Cel","volume":"134","author":"Neelapu","year":"2019","journal-title":"Blood"},{"key":"2025100300562845000_13.1.e008876.232","doi-asserted-by":"crossref","first-page":"E352","DOI":"10.1002\/ajh.25235","article-title":"Heterogeneity of surface CD19 and CD22 expression in B lymphoblastic leukemia","volume":"93","author":"Rosenthal","year":"2018","journal-title":"American J Hematol"},{"key":"2025100300562845000_13.1.e008876.233","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2019.01237","article-title":"Understanding the Mechanisms of Resistance to CAR T-Cell Therapy in Malignancies","volume":"9","author":"Cheng","year":"2019","journal-title":"Front Oncol"},{"key":"2025100300562845000_13.1.e008876.234","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0146-z"},{"key":"2025100300562845000_13.1.e008876.235","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001150","article-title":"Point mutation in CD19 facilitates immune escape of B cell lymphoma from CAR-T cell therapy","volume":"8","author":"Zhang","year":"2020","journal-title":"J Immunother Cancer"},{"key":"2025100300562845000_13.1.e008876.236","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0201-9"},{"key":"2025100300562845000_13.1.e008876.237","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-08-665547"},{"key":"2025100300562845000_13.1.e008876.238","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms12320","article-title":"CD19 CAR immune pressure induces B-precursor acute lymphoblastic leukaemia lineage switch exposing inherent leukaemic plasticity","volume":"7","author":"Jacoby","year":"2016","journal-title":"Nat Commun"},{"key":"2025100300562845000_13.1.e008876.239","doi-asserted-by":"crossref","first-page":"1980","DOI":"10.1182\/blood.2020005123","article-title":"Transdifferentiation of lymphoma into sarcoma associated with profound reprogramming of the epigenome","volume":"136","author":"Zhang","year":"2020","journal-title":"Blood"},{"key":"2025100300562845000_13.1.e008876.240","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-19-0813"},{"key":"2025100300562845000_13.1.e008876.241","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019002121"},{"key":"2025100300562845000_13.1.e008876.242","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-20-0756"},{"key":"2025100300562845000_13.1.e008876.243","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3838"},{"key":"2025100300562845000_13.1.e008876.244","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.0800997"},{"key":"2025100300562845000_13.1.e008876.245","doi-asserted-by":"publisher","DOI":"10.1038\/nri3862"},{"key":"2025100300562845000_13.1.e008876.246","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-019-0221-9"},{"key":"2025100300562845000_13.1.e008876.247","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2019-131041","article-title":"Tumor Inflammation and Myeloid Derived Suppressor Cells Reduce the Efficacy of CD19 CAR T Cell Therapy in Lymphoma","volume":"134","author":"Jain","year":"2019","journal-title":"Blood"},{"key":"2025100300562845000_13.1.e008876.248","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2016.217"},{"key":"2025100300562845000_13.1.e008876.249","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-16-0850"},{"key":"2025100300562845000_13.1.e008876.250","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2019.02453","article-title":"T Regulatory Cells and Priming the Suppressive Tumor Microenvironment","volume":"10","author":"Paluskievicz","year":"2019","journal-title":"Front Immunol"},{"key":"2025100300562845000_13.1.e008876.251","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-0426"},{"key":"2025100300562845000_13.1.e008876.252","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-01916-x"},{"key":"2025100300562845000_13.1.e008876.253","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1007\/s12254-017-0367-8","article-title":"Aggressive lymphoma 2016: revision of the WHO classification","volume":"10","author":"Beham-Schmid","year":"2017","journal-title":"Memo"},{"key":"2025100300562845000_13.1.e008876.254","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/35000501","article-title":"Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling","volume":"403","author":"Alizadeh","year":"2000","journal-title":"Nature New Biol"},{"key":"2025100300562845000_13.1.e008876.255","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-03-212191"},{"key":"2025100300562845000_13.1.e008876.256","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa012914"},{"key":"2025100300562845000_13.1.e008876.257","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-05-220095"},{"key":"2025100300562845000_13.1.e008876.258","doi-asserted-by":"publisher","DOI":"10.1038\/nm0102-68"},{"key":"2025100300562845000_13.1.e008876.259","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2116133"},{"key":"2025100300562845000_13.1.e008876.260","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2016.10.020"},{"key":"2025100300562845000_13.1.e008876.261","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2019.00168","article-title":"Cold Tumors: A Therapeutic Challenge for Immunotherapy","volume":"10","author":"Bonaventura","year":"2019","journal-title":"Front Immunol"},{"key":"2025100300562845000_13.1.e008876.262","doi-asserted-by":"crossref","DOI":"10.1038\/s41392-021-00812-z","article-title":"CAR-T: a potential gene carrier targeting solid tumor immune microenvironment","volume":"6","author":"Wang","year":"2021","journal-title":"Signal Transduct Target Ther"},{"key":"2025100300562845000_13.1.e008876.263","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminhematol.2018.08.008"},{"key":"2025100300562845000_13.1.e008876.264","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1089\/hum.2017.126","article-title":"CD20-CD19 Bispecific CAR T Cells for the Treatment of B-Cell Malignancies","volume":"28","author":"Martyniszyn","year":"2017","journal-title":"Hum Gene Ther"},{"key":"2025100300562845000_13.1.e008876.265","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/s40425-017-0246-1","article-title":"A tandem CD19\/CD20 CAR lentiviral vector drives on-target and off-target antigen modulation in leukemia cell lines","volume":"5","author":"Schneider","year":"2017","journal-title":"j immunotherapy cancer"},{"key":"2025100300562845000_13.1.e008876.266","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-15-0231"},{"key":"2025100300562845000_13.1.e008876.267","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-1081-3"},{"key":"2025100300562845000_13.1.e008876.268","first-page":"2470","article-title":"Dual targeting of CD19 and CD22 with bicistronic CAR-T cells in patients with relapsed\/refractory large B-cell lymphoma","volume":"141","author":"Roddie","year":"2023","journal-title":"Blood"},{"key":"2025100300562845000_13.1.e008876.269","doi-asserted-by":"publisher","DOI":"10.1172\/JCI83092"},{"key":"2025100300562845000_13.1.e008876.270","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2018-99-111523","article-title":"End of Phase 1 Results from Zuma-6: Axicabtagene Ciloleucel (Axi-Cel) in Combination with Atezolizumab for the Treatment of Patients with Refractory Diffuse Large B Cell Lymphoma","volume":"132","author":"Jacobson","year":"2018","journal-title":"Blood"},{"key":"2025100300562845000_13.1.e008876.271","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-019-0657-3"},{"key":"2025100300562845000_13.1.e008876.272","article-title":"Safety and efficacy of tisagenlecleucel (tisa-cel) plus pembrolizumab (pembro) in patients (pts) with relapsed\/refractory diffuse large B-cell lymphoma (r\/r DLBCL): Updated analysis of the phase 1b PORTIA study","volume":"39","author":"J\u00e4ger","year":"2021","journal-title":"J C O"},{"key":"2025100300562845000_13.1.e008876.273","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-11-679134"},{"key":"2025100300562845000_13.1.e008876.274","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-1527"},{"key":"2025100300562845000_13.1.e008876.275","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019002936"},{"key":"2025100300562845000_13.1.e008876.276","doi-asserted-by":"crossref","first-page":"5774","DOI":"10.1182\/bloodadvances.2022007317","article-title":"Anti-CD19 CAR T cells in combination with ibrutinib for the treatment of chronic lymphocytic leukemia","volume":"6","author":"Gill","year":"2022","journal-title":"Blood Adv"},{"key":"2025100300562845000_13.1.e008876.277","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1610544113"},{"key":"2025100300562845000_13.1.e008876.278","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.633205","article-title":"Natural Killer Cell Interactions With Myeloid Derived Suppressor Cells in the Tumor Microenvironment and Implications for Cancer Immunotherapy","volume":"12","author":"Zalfa","year":"2021","journal-title":"Front Immunol"},{"key":"2025100300562845000_13.1.e008876.279","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-18-0572"},{"key":"2025100300562845000_13.1.e008876.280","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-10-881722"},{"key":"2025100300562845000_13.1.e008876.281","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.AC119.007558"},{"key":"2025100300562845000_13.1.e008876.282","doi-asserted-by":"crossref","DOI":"10.1038\/s41421-021-00255-4","article-title":"CRISPR-edited CART with GM-CSF knockout and auto secretion of IL6 and IL1 blockers in patients with hematologic malignancy","volume":"7","author":"Yi","year":"2021","journal-title":"Cell Discov"},{"key":"2025100300562845000_13.1.e008876.283","doi-asserted-by":"publisher","DOI":"10.1080\/14712598.2020.1738378"},{"key":"2025100300562845000_13.1.e008876.284","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12092567","article-title":"The Landscape of CAR-T Cell Clinical Trials against Solid Tumors-A Comprehensive Overview","volume":"12","author":"Schaft","year":"2020","journal-title":"Cancers (Basel)"},{"key":"2025100300562845000_13.1.e008876.285","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-21-0407"},{"key":"2025100300562845000_13.1.e008876.286","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1038\/s41586-022-04489-4","article-title":"GD2-CAR T cell therapy for H3K27M-mutated diffuse midline gliomas","volume":"603","author":"Majzner","year":"2022","journal-title":"Nature New Biol"},{"key":"2025100300562845000_13.1.e008876.287","doi-asserted-by":"publisher","DOI":"10.1126\/science.aay5967"},{"key":"2025100300562845000_13.1.e008876.288","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2210859"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2024-008876","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T07:56:54Z","timestamp":1759478214000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2024-008876"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":288,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,1,16]]},"published-print":{"date-parts":[[2025,1]]}},"alternative-id":["10.1136\/jitc-2024-008876"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2024-008876","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1]]}}}